Clinical Trial: Cancer

STRATA STR‐001‐001 Biospecimen Study

Full Name

An Observational Study Profiling Biospecimens from Cancer Patients to Screen for Molecular Alterations


Many patients are treated for advanced cancer without knowledge of underlying molecular features that might indicate FDA approved therapies or potential eligibility for biomarker-selected clinical trials. Strata Oncology is initiating the Strata Trial (STR-001-001) with the primary goal of understanding the proportion of subjects available for clinical trials and approved targeted therapies in advanced cancer while assessing the feasibility of using a large-scale NGS screening program to match subjects for eligibility assessments in clinical trials and/or for approved targeted therapies. The Strata Trial does not require additional procedures but rather uses surplus, or leftover tumor specimens for molecular profiling.


Inclusion Criteria

Subjects must be ≥ 18 years of age.
Subjects must have histologically documented solid tumors or lymphoma.
Specific criteria for individual tumor types are as follows:
a. Subjects with glioblastoma.
b. Subjects with pancreatic cancer are eligible at any stage of disease.
c. Subjects with rare tumors (i.e. cancer started in an unusual place in the body, it is unusual type and requires special treatment) are eligible at stages II-IV
d. Subjects with other tumor types must have recurrent, relapsed, refractory, metastatic or advanced stages III or IV cancer.
Subjects must have an adequate formalin-fixed paraffin-embedded tumor specimen for genomic sequencing.

Doctor(s) Running This Study